Previous close | 8.21 |
Open | 8.10 |
Bid | 7.67 x 100 |
Ask | 7.94 x 100 |
Day's range | 7.76 - 8.34 |
52-week range | 3.21 - 9.96 |
Volume | |
Avg. volume | 73,574 |
Market cap | 237.822M |
Beta (5Y monthly) | 1.49 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.81 |
Earnings date | 08 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 15 Jul 2021 |
1y target est | N/A |
Key Insights XBiotech's significant retail investors ownership suggests that the key decisions are influenced by...
XBiotech Architectural Rendition of XBiotech’s Planned R&D Facility XBiotech Architectural Rendition of XBiotech’s Planned R&D Facility AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- XBiotech Inc. today announced that it plans to expand it’s campus headquarters with the construction of a new, state-of-the-art research and development facility. XBiotech has received City of Austin approval to begin excavation for site preparation and groundwork is expected to begin 1st quarter 2024. The new fou
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...